CSIMarket
 
Skye Bioscience Inc   (SKYE)
Other Ticker:  
 
 
Price: $13.2100 $0.31 2.403%
Day's High: $16.01 Week Perf: -0.86 %
Day's Low: $ 13.00 30 Day Perf: 106.08 %
Volume (M): 32 52 Wk High: $ 19.41
Volume (M$): $ 419 52 Wk Avg: $4.52
Open: $13.00 52 Wk Low: $1.44



 Market Capitalization (Millions $) 104
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Skye Bioscience Inc
Skye Bioscience Inc is a biotechnology company focused on developing and commercializing novel therapeutics for various medical conditions. The company's primary area of research is the endocannabinoid system, which plays a crucial role in regulating various physiological processes. Skye Bioscience aims to leverage its expertise in this area to develop innovative drugs that target specific components of the endocannabinoid system to address unmet medical needs. The company's pipeline includes potential treatments for glaucoma, ocular inflammation, and neuroinflammatory conditions. Skye Bioscience is committed to advancing its drug candidates through rigorous clinical development and regulatory approval processes to bring transformative therapies to patients.


   Company Address: 11250 El Camino Real, San Diego 92130 CA
   Company Phone Number: 410-0266   Stock Exchange / Ticker: SKYE
   SKYE is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Skye Bioscience Takes a Promising Step Forward in Glaucoma Treatment with SBI-100 Ophthalmic Emulsion

Published Tue, Nov 28 2023 12:00 PM UTC

Skye Bioscience, a pharmaceutical company specializing in targeting the endocannabinoid system, recently announced that it has treated the first patient in its Phase 2 clinical trial for SBI-100 Ophthalmic Emulsion (OE). This trial aims to evaluate the emulsion's ability to lower intraocular pressure (IOP), its safety profile, and relevant biomarkers in patients suffering fr...

Skye Bioscience Inc

Skye Bioscience Inc Faces Concerns as Operating Loss Declared in Third Quarter of 2023

The recent financial reports from Skye Bioscience Inc have not been promising, causing concern among stockholders. During the July to September 30th reporting season in 2023, the company did not show any improvements in its top-line figures. However, the focus of investors was directed towards the operating loss, which came in at a staggering $-24.705766 million for the same period.
The lack of positive financial performance is a major red flag for Skye Bioscience Inc. As the company enters its current cycle, market expectations are high for additional revenue sources to be generated in the near future. However, investors are not relying on the company's recent execution in the Major Pharmaceutical Preparations industry to deliver those desired results.

Skye Bioscience Inc

Skye Bioscience Inc Shows Impressive Gain in Q2 2023 despite $2.84M Operating Loss: A Remarkable Milestone for Shareholders!

In the Major Pharmaceutical Preparations industry, smaller businesses are now reporting their financial results alongside the bellwethers. SKYE Bioscience Inc recently announced an operating loss of $-2.842997 million for the second quarter of 2023. While the loss may seem concerning at first, it is worth noting that SKYE's operating loss has actually improved compared to the second quarter of 2022, where it stood at $-3.21836 million. This positive development has provided some reassurance to investors.
Furthermore, SKYE Bioscience Inc has successfully decreased its deficit from $-3.419 million to $-3.112 million in the second quarter of 2022. This reduction in deficit signals potential progress on their path to becoming a prominent player in the industry.

Skye Bioscience Inc

Skye Bioscience Inc reports staggering operating shortfall of $-3.1 million in Q1 2023 earnings, sparking investor concern

In the latest news from the major pharmaceutical preparations sector, industry veterans are still analyzing the first quarter performance of 2023. One particular company that they are watching closely is Skye Bioscience Inc, which has not yet stated any revenue for the period ranging from January to March 2023.
What has raised eyebrows is the operating shortfall of $-3.100158 million, which has worsened from the previous year's first quarter performance of $-2.888021 million. This is an issue that the company needs to address, as it is important for investors to see a healthy revenue stream.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com